265 related articles for article (PubMed ID: 34103383)
1. Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database.
Kim H; Pfeiffer CM; Gray MP; Stottlemyer BA; Boyce RD; Kane-Gill SL
Respir Care; 2021 Nov; 66(11):1739-1745. PubMed ID: 34103383
[TBL] [Abstract][Full Text] [Related]
2. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
Ismaila AS; Birk R; Shah D; Zhang S; Brealey N; Risebrough NA; Tabberer M; Zhu CQ; Lipson DA
Adv Ther; 2017 Sep; 34(9):2163-2172. PubMed ID: 28875459
[TBL] [Abstract][Full Text] [Related]
3. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
Bjermer LH; Boucot IH; Vogelmeier CF; Maltais F; Jones PW; Tombs L; Compton C; Lipson DA; Kerwin EM
Adv Ther; 2021 Sep; 38(9):4815-4835. PubMed ID: 34347255
[TBL] [Abstract][Full Text] [Related]
5. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
O'Shea O; Stovold E; Cates CJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD007694. PubMed ID: 33852162
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
7. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
[TBL] [Abstract][Full Text] [Related]
8. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
[TBL] [Abstract][Full Text] [Related]
9. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
10. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Blair HA; Deeks ED
Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
12. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
Lipson DA; Birk R; Brealey N; Zhu CQ
Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
[TBL] [Abstract][Full Text] [Related]
13. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
15. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Kalhan R; Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1149-1161. PubMed ID: 33911860
[TBL] [Abstract][Full Text] [Related]
16. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
Aagaard L; Hansen EH
Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
[TBL] [Abstract][Full Text] [Related]
17. Comparison table: Inhaled corticosteroids for treatment of COPD.
Med Lett Drugs Ther; 2020 Sep; 62(1606):e148-e149. PubMed ID: 32960875
[No Abstract] [Full Text] [Related]
18. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
[TBL] [Abstract][Full Text] [Related]
19. [Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease].
Bolotova EV; Dudnikova AV; Shulzhenko LV
Ter Arkh; 2022 Mar; 94(3):396-400. PubMed ID: 36286904
[TBL] [Abstract][Full Text] [Related]
20. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
